Mostrando 1 - 20 Resultados de 424 Para Buscar '"Genentech"', tiempo de consulta: 0.29s Limitar resultados
  1. 1
    por Baldwin, A Lane, Cook-Deegan, Robert
    Publicado 2013
    “…Despite these similarities, time has reduced the narrative to that of hero versus villain: Genentech is lauded - at least for the final outcome of the Herceptin(® )story - as a corporate good citizen, Myriad as a ruthless mercenary. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Constructing narratives of heroism and villainy: case study of Myriad's BRACAnalysis(® )compared to Genentech's Herceptin(®)
  2. 2
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS)
  3. 3
    “…Hoffman La Roche: Stocks/Bonds Shih-Chen Cheng, M.S., P.h.D, Genentech/F. Hoffman La Roche: Genentech Employee|Genentech/F. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
  4. 4
    “…Rymut, PhD, Genentech (Employee, Shareholder) Aklile Berhanu, PhD, Genentech, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    167. A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with staphylococcus Aureus Bacteremia Receiving Standard-of-care Antibiotics
  5. 5
    “…Hoffmann-La Roche Ltd. (Shareholder)Genentech, Inc. (Employee) Yifeng Chia, PhD, F. Hoffmann-La Roche Ltd (Shareholder)Genentech, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    515. Evolution of Treatment Patterns for Patients Hospitalized with COVID-19 in the United States
  6. 6
    “…DISCLOSURES: Yasin Abdul, MD, Genentech: Grant/Research Support Ed Davidson, PharmD, MPH, Genentech: Grant/Research Support Kevin McConeghy, PharmD, Genentech: Grant/Research Support|Pfizer: Grant/Research Support|Sanofi-Pasteur: Grant/Research Support|Seqirus: Grant/Research Support Kaley Hayes, PharmD, PhD, Sanofi Aventis: Grant/Research Support Lisa Han, MPH, Genentech: Grant/Research Support Melissa LaMantia, MA, Genentech: Grant/Research Support Elie Saade, MD, Envision Pharma: Speaker, Presenter|Johnson and Johnson: Speaker, Travel, Lodging|Protein Sciences Corp: Grant/Research Support|Sanofi Pasteur: Speaker, Travel, Lodging David Canaday, MD, Pfizer: Grant/Research Support Stefan Gravenstein, MD, MPH, CDC: Grant/Research Support|Genentech: Advisor/Consultant|Genentech: Grant/Research Support|GSK: Advisor/Consultant|GSK: Honoraria|Janssen: Advisor/Consultant|Janssen: Honoraria|NIH: Grant/Research Support|Pfizer: Grant/Research Support|Pfizer: Honoraria|Sanofi: Advisor/Consultant|Sanofi: Grant/Research Support|Sanofi: Honoraria|Seqirus: Grant/Research Support|Seqirus: Honoraria…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    901. The Impact of Cost-Free On-Site Influenza Point of Care Antigen Testing on Influenza Detection in Nursing Homes
  7. 7
    “…Peck, MD, PhD, Genentech (Employee)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1305. Comparison of Pharmacokinetics of DSTA4637S, a novel THIOMAB(TM) Antibody-Antibiotic Conjugate, in Patients with Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics with Pharmacokinetics in Healthy Volunteers
  8. 8
    “…DISCLOSURES: Nate Way, PhD, Genentech, Inc. (Grant/Research Support)Kantar Health (Employee) Ashley Martin, PhD, Genentech, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    801. Patient Reported Experience with Influenza Episode and Impact on Life and Work
  9. 9
    “…(Shareholder)Genentech, Inc. (Employee) Yifeng Chia, PhD, F. Hoffmann-La Roche Ltd (Shareholder)Genentech, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    322. Risk Factors for COVID-19 Disease Severity Using Electronic-Health Records in a Real-World Cohort in the United States
  10. 10
    “…METHODS: Internal Roche/Genentech data sources: Cases of COVID-19 from ongoing Roche/Genentech clinical trials and from post-marketing use of ocrelizumab until July 31, 2020 were identified and assessed using descriptive statistics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 in ocrelizumab-treated people with multiple sclerosis
  11. 11
    “…DISCLOSURES: Nate Way, PhD, Genentech, Inc. (Grant/Research Support)Kantar Health (Employee) Ashley Martin, PhD, Genentech, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1345. Patient Perspectives and Journey with Influenza and Seeking Care from US National Survey
  12. 12
    “…I.C. and B.X. are employees and stockholders of Genentech.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis
  13. 13
    “…Combined with business processes and risk management, these pillars rapidly allowed casirivimab and imdevimab to move to clinical manufacturing and to production at Genentech in a first-time process transfer under compressed timelines between the companies.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail
  14. 14
    “…(Shareholder)Genentech, Inc. (Employee) Larry Tsai, MD, F. Hoffmann-La Roche Ltd (Shareholder)Genentech, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    26. Risk of Post–COVID-19 Dyspnea and Interstitial Lung Disease (ILD) in a Real-World Cohort of Patients Hospitalized with COVID-19 in the United States
  15. 15
    “…DISCLOSURES: Eddie Neuberger, PharmD, Genentech, Inc. (Employee) Chris Wallick, PharmD, MS, Genentech, Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1518. Real-World Comparative Effectiveness of Baloxavir Marboxil versus Oseltamivir on Influenza-Related Complication and Resource Utilization
  16. 16
    “…(Shareholder)Genentech, Inc. (Employee)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    281. Prevalence of Influenza Co-infection in a Real-world Cohort of COVID-19 Patients in the U.S
  17. 17
    por Keane, Pearse A, Sadda, Srinivas R
    Publicado 2011
    “…Fortunately however, the recent introduction of antivascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis(®), Genentech, South San Francisco, CA) and bevacizumab (Avastin(®), Genentech), offers a potentially new treatment approach for clinicians managing this disorder. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
  18. 18
    por Kamath, Amrita V., Iyer, Suhasini
    Publicado 2015
    “…Current tools that are available and strategies to enable appropriate assessment are also discussed. © 2015 Genentech Inc. Biopharmaceutics & Drug Disposition Published by John Wiley & Sons Ltd.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
  19. 19
    “…PN was the most frequent adverse event resulting in dose modifications and/or discontinuation of treatment for valine‐citrulline‐monomethylauristatin E antibody–drug conjugates (ADCs) developed at Genentech. A pooled time‐to‐event analysis across eight ADCs (~700 patients) was performed to evaluate the relationship between the ADC exposure and the risk for developing a clinically significant (grade ≥ 2) PN. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates
  20. 20
    “…METHOD: We used a curated data set from 104 completed Roche/Genentech sponsored clinical studies to train a machine learning model to predict the expected number of AEs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning
Herramientas de búsqueda: RSS